The disclosure of the 2024 quarterly report is nearing completion. Judging from the information already disclosed, during the reporting period, the total operating revenue of innovative pharmaceutical companies on the Science and Technology Innovation Board exceeded 11 billion yuan, an increase of more than 40% over the previous year; net profit to mother was nearly 4 billion yuan, turning a loss into a profit over the previous year, and ushered in a “good start.”
国产创新药迎来政策春风 科创板创新药企业实现“开门红”
Domestic innovative drugs ushered in policies, spring wind, science and technology innovation board innovative drug companies achieved a “good start”
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.